A pharmacoepidemiological study of rivaroxaban use and potential adverse outcomes in routine clinical practice in SwedenFirst published 09/06/2015 Last updated 23/04/2024 EU PAS number: EUPAS9895StudyFinalisedDownload as PDF
Friberg Research AB, Karolinska InstituteSweden First published: 19/03/2014Last updated 26/03/2014 InstitutionEducational InstitutionHospital/Clinic/Other health care facilityLaboratory/Research/Testing facilityENCePP partner